XML 10 R1.htm IDEA: XBRL DOCUMENT v3.25.1
Document And Entity Information - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Mar. 19, 2025
Jun. 30, 2024
Cover [Abstract]      
Document Type 10-K    
Entity Central Index Key 0001357459    
Entity Registrant Name PALISADE BIO, INC.    
Amendment Flag false    
Current Fiscal Year End Date --12-31    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2024    
Document Annual Report true    
Document Period End Date Dec. 31, 2024    
Document Transition Report false    
Entity File Number 001-33672    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 52-2007292    
Entity Address, Address Line One 7750 El Camino Real, Suite 2A    
Entity Address, City or Town Carlsbad    
Entity Address, State or Province CA    
Entity Address, Postal Zip Code 92009    
City Area Code 858    
Local Phone Number 704-4900    
Title of 12(b) Security common stock, $0.01 par value    
Trading Symbol PALI    
Security Exchange Name NASDAQ    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
ICFR Auditor Attestation Flag false    
Document Financial Statement Error Correction [Flag] false    
Entity Shell Company false    
Entity Common Stock, Shares Outstanding   4,396,646  
Entity Public Float     $ 4.3
Auditor Firm ID 23    
Auditor Name Baker Tilly US, LLP    
Auditor Location New York, New York    
Auditor Opinion

We have audited the accompanying consolidated balance sheets of Palisade Bio, Inc. (the "Company") as of December 31, 2024 and 2023, the related consolidated statements of operations, stockholders' equity, and cash flows, for each of the two years in the period ended December 31, 2024, and the related notes (collectively referred to as the "consolidated financial statements"). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2024, in conformity with accounting principles generally accepted in the United States of America.

    
Documents Incorporated by Reference

DOCUMENTS INCORPORATED BY REFERENCE

None.